Sourcebio International - SBI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 220
  • Forecasted Upside: 95.56 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 112.50
+0 (0.00%)

This chart shows the closing price for SBI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sourcebio International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBI

Analyst Price Target is GBX 220
▲ +95.56% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sourcebio International in the last 3 months. The average price target is GBX 220, with a high forecast of GBX 220 and a low forecast of GBX 220. The average price target represents a 95.56% upside from the last price of GBX 112.50.

This chart shows the closing price for SBI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Sourcebio International.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/5/2022Liberum CapitalBoost TargetBuyGBX 210 ➝ GBX 220
3/8/2022Liberum CapitalBoost TargetBuyGBX 205.30 ➝ GBX 220
1/18/2022Liberum CapitalBoost TargetBuyGBX 190 ➝ GBX 205.30
12/10/2021Liberum CapitalReiterated RatingBuyGBX 190
10/22/2021Liberum CapitalReiterated RatingBuyGBX 190
7/27/2021Liberum CapitalReiterated RatingBuyGBX 230
4/13/2021Liberum CapitalReiterated RatingBuyGBX 230
(Data available from 12/4/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sourcebio International logo
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. The company's services cover histopathology cancer screening and clinical diagnostic services; DNA sequencing services and precision medicine to pharmaceutical and biotechnology companies, academia, contract research organizations, and other research markets; shelf-life testing services and equipment; and COVID-19 antigen PCR testing services. It also manufactures library clones, direct to consumer home test kits, and blood and tissue serological products; and provides employee testing solutions and venue testing. In addition, the company offers controlled environment storage services and diagnostic and genomic services and products. Sourcebio International Plc was founded in 1999 and is headquartered in Nottingham, the United Kingdom.
Read More

Today's Range

Now: GBX 112.50
Low: 110.30
High: 112.50

50 Day Range

MA: GBX 114.83
Low: 105
High: 130

52 Week Range

Now: GBX 112.50
Low: 105
High: 170

Volume

9,347 shs

Average Volume

85,813 shs

Market Capitalization

£83.46 million

P/E Ratio

1,250.00

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sourcebio International?

The following equities research analysts have issued research reports on Sourcebio International in the last twelve months: Liberum Capital.
View the latest analyst ratings for SBI.

What is the current price target for Sourcebio International?

1 Wall Street analysts have set twelve-month price targets for Sourcebio International in the last year. Their average twelve-month price target is GBX 220, suggesting a possible upside of 95.6%. Liberum Capital has the highest price target set, predicting SBI will reach GBX 220 in the next twelve months. Liberum Capital has the lowest price target set, forecasting a price of GBX 220 for Sourcebio International in the next year.
View the latest price targets for SBI.

What is the current consensus analyst rating for Sourcebio International?

Sourcebio International currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBI will outperform the market and that investors should add to their positions of Sourcebio International.
View the latest ratings for SBI.

What other companies compete with Sourcebio International?

How do I contact Sourcebio International's investor relations team?

Sourcebio International's physical mailing address is 620 Eighth Avenue, New York, New York 10018. The company's listed phone number is 44 11 5973 9012. The official website for Sourcebio International is www.sourcebioscience.com. Learn More about contacing Sourcebio International investor relations.